- Mahindra & Mahindra reported a 5% fall in auto sales for September 2015 compared to the same period last year. Domestic sales fell 7.46% while exports grew 26%. - Suven Life Sciences secured three new patents related to treatments for neurodegenerative disorders, bringing their total patents to 24 in New Zealand and 22 each in Singapore and the US. - Technical indicators suggest selling M&M around 1250-1258 levels with a target of 1225 and stop loss of 1271, and buying Suven around 284-286 levels with a target of 292 and stop loss of 281.

1. SEBI Certified – Research Analyst www.choiceindia.com
Global View
India Update
Today’s Event/ Stock in News
Mahindra & Mahindra (M&M), India's leading SUV manufacturer, has reported its auto sales numbers which stood at 42,848 units during September 2015 as
against 44,911 units during September 2014, registering a fall of 5%. The Passenger Vehicles segment (which includes UVs, Cars and Vans) sold 19,564 units in
September 2015 as against 21,141 units during September 2014, down by 7.46%. The company's domestic sales stood at 39,693 units during September 2015 as
against 42,408 units during September 2014. The company's exports for September 2015 stood at 3,155 units registering a growth of 26%. Mahindra & Mahindra
(M&M) is the flagship company of the Mahindra Group, a multinational conglomerate based in Mumbai, India. Amongst the various business interests of its
parent group, the company is mainly involved in the automobile manufacturing. It is one of the leading auto companies of India.
Technical Outlook : The stock has been facing resistance of 50% Fibonacci retracement of previous down move from 1442.05 to 1092.75 levels.
Moreover, price has formed bearish engulfing candle stick pattern which is bearish reversal pattern. Recently, prices are trading below 60
DEMA which suggest short to medium term trend is down. The momentum indictor RSI has remained below 60 levels on daily chart which gives
negative confirmation to the prices. So for trading perspective, one could Sell in the range of 1250-1258 for the Target of 1225 with the SL of
1271.
Suven Life Sciences has secured one product patent from New Zealand, one product patent from Singapore and one product patent from USA corresponding to
the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2032. The
granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful
in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder
(ADHD), Huntington's disease, Parkinson and Schizophrenia. With these new patents, Suven has a total of 24 granted patents from New Zealand, 22 granted
product patents from Singapore and 22 granted patents from USA. These granted patents are exclusive intellectual property of Suven and are achieved through
the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in
class or best in class CNS therapies through the use of GPCR targets.
Technical Outlook: On daily chart, price has given breakout of horizontal channel formation at 276.20 levels. Moreover, price has also given
breakout of its flag pattern on daily chart with above average volumes, which is continuation pattern. Prices have been trading above 200
DEMA which indicates long term trend is up. On the other, momentum indictor RSI has moved above 60 levels which add bullishness to the
prices. So for trading perspective, one could Buy in the range of 284-286 for the Target of 292 with the SL of 281.
M&M
SUVEN
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Morning Tea
05th Oct 2015
Buy in the range of 284-286 for the Target of 292 with the SL of 281
Sell in the range of 1250-1258 for the Target of 1225 with the SL of 1271
US stocks closed more than 1 percent higher, recovering from an initial decline of more than 1.5 percent, as investors digested higher oil prices
and a weaker-than-expected jobs report. The US economy added 142,000 jobs in September versus expectations of over 200,000 jobs. August's
number was also revised sharply lower, thereby reducing the probability of a Fed rate hike in 2015. The Dow and S&P 500 closed up more than
1 percent for their biggest intraday upside reversal since October 4, 2011. The Dow Jones industrial average rose 200 points, or 1.23 percent, to
16,472.37, the S&P 500 gained 27.54 points, or 1.43 percent, to 1951.36, and the Nasdaq Composite added 80.70 points, or 1.74 percent, to
4707.78
Asian equities kicked off the trading week on a positive note after a weak US employment report on Friday cooled expectations that the Federal
Reserve will start raising interest rates soon. Markets in China remain closed until Wednesday for National Day holidays. September's closely-
watched jobs report showed the US economy created 142,000 jobs, far below the expected 203,000. Unemployment held at 5.1 percent while
the participation rate plunged to 62.4 percent, according to the Labor Department. Indications of softness in the labor market mean the Fed is
unlikely to begin tightening monetary policy soon, analysts say. The Shanghai Composite index traded at 0.50% to 3053.32, Hang Seng index
traded at 1.72 % to 21882.93, Japan's benchmark Nikkei 225 index traded at 1.21% to 17941.62, South Korea's Kospi index up by 1.13 % to
1992.11 levels. The SGX Nifty suggests a positive opening for our markets as it is trading at 8039.50, up by 81 points.

2. SEBI Certified – Research Analyst www.choiceindia.com
Bulk Deal
Corporate Action / Result Calendar
SEBI Certified – Research Analyst www.choiceindia.com
Morning Tea
Corporate Action:
05th Oct 2015
Security in Ban
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Sr.No Deal Date Security Code Security Name Client Name Deal Type Quantity Price
1 1/10/2015 533288 CLARIS BARCLAYS CAPITAL MAURITIUS LIMITED S 770914 201.28
2 1/10/2015 533288 CLARIS RELIANCE MUTUAL FUND B 625000 201.00
3 1/10/2015 532927 ECLERX FRANKLIN TEMPLETON MUTUAL FUND B 250000 1575.00
4 1/10/2015 534060 PMCFIN BRIJKISHOR VANIJYA PRIVATE LIMITED S 150000 1.06
5 1/10/2015 534731 BITL PRATYAKSHYA SHAREBROKERS PVTLTD B 100000 36.99
6 1/10/2015 539363 SKC BCB BROKERAGE PRIVATE LIMITED B 84000 41.39
7 1/10/2015 512301 CHMBBRW JITENDRA SHARMA S 74475 15.68
8 1/10/2015 512301 CHMBBRW JITENDRA SHARMA B 74475 15.24
9 1/10/2015 534708 RCRL BHANUBEN VASANTBHAI RAVANI S 66000 14.25
10 1/10/2015 539363 SKC SURESH KUMAR B 51000 41.85

3. SEBI Certified – Research Analyst www.choiceindia.com
Contact Us
www.choiceindia.com
www.choiceindia.comcustomercare@choiceindia.com
Disclaimer
This is solely for information of clients of Choice Broking and does not construe to be an investment advice. It is also not intended as an offer or solicitation for the purchase and sale of any financial
instruments. Any action taken by you on the basis of the information contained herein is your responsibility alone and Choice Broking its subsidiaries or its employees or associates will not be liable in
any manner for the consequences of such action taken by you. We have exercised due diligence in checking the correctness and authenticity of the information contained in this recommendation, but
Choice Broking or any of its subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the
information contained in this recommendation or any action taken on basis of this information. Technical analysis studies market psychology, price patterns and volume levels. It is used to forecast
future price and market movements. Technical analysis is complementary to fundamental analysis and news sources. The recommendations issued herewith might be contrary to recommendations
issued by Choice Broking in the company research undertaken as the recommendations stated in this report is derived purely from technical analysis. Choice Broking has based this document on
information obtained from sources it believes to be reliable but which it has not independently verified; Choice Broking makes no guarantee, representation or warranty and accepts no responsibility
or liability as to its accuracy or completeness. The opinions contained within the report are based upon publicly available information at the time of publication and are subject to change without
notice. The information and any disclosures provided herein are in summary form and have been prepared for informational purposes. The recommendations and suggested price levels are intended
purely for trading purposes. The recommendations are valid for the day of the report however trading trends and volumes might vary substantially on an intraday basis and the recommendations may
be subject to change. The information and any disclosures provided herein may be considered confidential. Any use, distribution, modification, copying, forwarding or disclosure by any person is
strictly prohibited. The information and any disclosures provided herein do not constitute a solicitation or offer to purchase or sell any security or other financial product or instrument. The current
performance may be unaudited. Past performance does not guarantee future returns. There can be no assurance that investments will achieve any targeted rates of return, and there is no guarantee
against the loss of your entire investment.
POTENTIAL CONFLICT OF INTEREST DISCLOSURE (as on date of report) Disclosure of interest statement – • Analyst interest of the stock /Instrument(s): - No. • Firm interest of the stock /
Instrument (s): - No.
SEBI Certified – Research Analyst www.choiceindia.com
Research Team
Mr. Sumeet Bagadia Associate Director
Kunal Parmar Research Associate
Ritesh Patel Research Associate
Amit Pathania Research Associate
Vikas Chaudhari Research Associate
Rajnath Yadav Research Associate
Satish Kumar Research Associate
Morning Tea
05th Oct 2015
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Kunal Parmar
Digitally signed by Kunal Parmar
DN: cn=Kunal Parmar, o=Choice Equity Broking
Pvt Ltd., ou=Research Dept.,
email=kunal.parmar@choiceindia.com, c=IN
Date: 2015.10.05 08:40:00 +05'30'